Taking your genes in hand
By The Economist,
The Economist
| 12. 06. 2007
Personal genetic testing is advancing rapidly. But beware of overselling
GENETIC testing promises a lot. In particular, it promises to tell people things ranging from their risks of developing ailments as diverse as heart disease, cancer and autism to how much coffee they can safely drink. It also promises a lucrative market for those doing the testing. Single-gene tests, such as those for particular forms of genes that predispose people to breast cancer, have been available for a while. This year, however, has seen the arrival of commercial versions of techniques that can sample a person's entire genetic make-up, and do so in a way that will enable him to benefit from future discoveries as well as existing knowledge.
In many cases, knowing the risk will also allow (and might, indeed, encourage) someone to modify his behaviour to avoid a disease he is at risk of—or, failing that, to mitigate its consequences. Nevertheless, concerns are being raised about the accuracy of some tests now on the market, and also their usefulness when the results are supplied direct to consumers, rather...
Related Articles
By Sarah Zhang, The Atlantic | 03.18.2024
People are discovering the truth about their biological parents with DNA—and learning that incest is far more common than many think.
When Steve Edsel was a boy, his adoptive parents kept a scrapbook of newspaper clippings in their bedroom closet...
By Antonio Regalado, MIT Technology Review | 03.20.2024
There is a new most expensive drug ever—a gene therapy that costs as much as a Brooklyn brownstone or a Miami mansion, and more than the average person will earn in a lifetime.
Lenmeldy is a gene treatment for metachromatic...
By Carl Zimmer, The New York Times | 03.10.2024
In 1889, a French doctor named Francois-Gilbert Viault climbed down from a mountain in the Andes, drew blood from his arm and inspected it under a microscope. Dr. Viault’s red blood cells, which ferry oxygen, had surged 42 percent. He...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...